They are not "going after everything". Anavex is carefully targeting indications that have a low SOC and a high pricing potential. All indications being pursued appear to be related in the likely response to the 2-73 MOA. That is a very wise use of resources.
Given the apparent MOA of 2-73, going "after everything" is not "very dangerous," but very logical as an exploration of the drug. This is not a case where a CEO cannot focus; Missling is intensely focused. This is not a case where a CEO is being profligate by pursuing poorly supported indications; Missling has been frugal and has only pursued indications with strong preclinical results.
You are seriously underestimating both management and the science.
Market Data 
Markets 
AI
